Life Scientist > Lab Technology

Biocomm names Canadian as chief operating officer

04 September, 2002 by Iain Scott

Melbourne-based life science commercialisation company Biocomm Services has appointed former Calgary Innovation Centre (CIC) executive director Lawrence Bremner as its new chief operating officer.


Former GroPep CEO Ballard launches angel fund

03 September, 2002 by Melissa Trudinger

A new business angel network, BioAngels Inc, has been launched in Adelaide by former GroPep CEO John Ballard.


Name change for Sydney institute

03 September, 2002 by Melissa Trudinger

The Institute of Respiratory Medicine in Sydney has changed its name to the Woolcock Institute of Medical Research in honour of its founding director Prof Ann Woolcock AO.


Final week for award nominations

03 September, 2002 by Iain Scott

There's barely a week left for you to enter the inaugural Australian Biotechnology News awards, but the good news is that you still have time.


Singapore feature: money or nothing: Australia versus Singapore Inc.

02 September, 2002 by David Binning

The comparison of the Australian and Singaporean biotech sectors highlights a fundamental principle of this highly volatile business: biotech needs lots of cash, but money burns pretty fast without good brains to spend it.


Researchers back beleaguered Trounson

29 August, 2002 by Melissa Trudinger

Leading scientists came out today in support of beleaguered Stem Cell Centre of Excellence CEO Prof Alan Trounson, and urged the Federal government to pass the Stem Cell Bill, which is expected to go to a vote in the House of Representatives later today.


ASX to help lift biotech's public image

28 August, 2002 by Melissa Trudinger

The Australian Stock Exchange is poised to take an active role in the development of a healthy public biotech sector in Australia.


Investment feature: patently obvious

27 August, 2002 by David Binning

To most, patents are the life blood of innovation and discovery for the biotech sector, while to others they are a scourge. But as lawyers and industry experts warn, careless handling of the finer points of intellectual property can be catastrophic to both commercial and academic organisations.


Investment feature: public image Ltd

27 August, 2002 by Tanya Hollis

Much is made of Australia's scientific intellectual capital and the opportunities that it offers. But according to one of the world's largest accounting groups, it is a dangerous myth that states successful companies will automatically flow from the nation's renowned research achievements.


Location, location, location: where should you build your biobusiness?

26 August, 2002 by David Binning

The most important concept for Australian biotechnology companies to grasp when building a nest, according to industry and property development experts, is proximity.


US VC warns of early IPO dangers

23 August, 2002 by Melissa Trudinger

Don't go public too early, use incubators to get your company off the ground and maximise collaborative opportunities, were the key messages from US venture capitalist Peter Morgan Kash at the AusBiotech 2002 conference this week.


Second BIF grant gives Protagonist an edge

22 August, 2002 by Pete Young

For drug design start-up Protagonist, tucking a second BIF grant in as many years under its belt should help smooth future discussions with commercial partners.


Heavy R&D spend sees Antisense book $6.3m loss

22 August, 2002 by David Binning

Biopharmaceutical research and development company Antisense Therapeutics reported on Wednesday a net loss of $6.3 million for the 12 months to June 30, 2002, driven largely by heavy early-stage expenditure on R&D, the company said.


IDT posts profit record number eight

22 August, 2002 by David Binning

Australian drug discovery company International Drug Technologies has announced a record 14 per cent jump in full year net profit to $4.2 million.


Put your pedal to the metal: BIO chief

20 August, 2002 by Melissa Trudinger

It's time for biobusiness to accelerate without looking back, the chair of the US Biotechnology Industry Organisation (BIO), David Robinson, told the AusBiotech conference in Melbourne this week.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd